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Abstract
Background: Li-Fraumeni syndrome is caused by germline TP53 mutations and is clinically characterized by a predisposition
to a range of cancers, most commonly sarcoma, brain tumours and leukemia. Pathogenic mosaic TP53 mutations have only
rarely been described.
Methods and Findings: We describe a 2 years old child presenting with three separate cancers over a 6 month period; two
soft tissue mesenchymal tumors and an aggressive metastatic neuroblastoma. As conventional testing of blood DNA by
Sanger sequencing for mutations in TP53, ALK, and SDH was negative, whole exome sequencing of the blood DNA of the
patient and both parents was performed to screen more widely for cancer predisposing mutations. In the patient’s but not
the parents’ DNA we found a c.743 G.A, p.Arg248Gln (CCDS11118.1) TP53 mutation in 3–20% of sequencing reads, a level
that would not generally be detectable by Sanger sequencing. Homozygosity for this mutation was detected in all tumor
samples analyzed, and germline mosaicism was demonstrated by analysis of the child’s newborn blood spot DNA. The
occurrence of separate tumors derived from different germ layers suggests that this de novo mutation occurred early in
embryogenesis, prior to gastrulation.
Conclusion: The case demonstrates pathogenic mosaicim, detected by next generation deep sequencing, that arose in the
early stages of embryogenesis.
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Introduction
Germline mutations in the TP53 gene cause Li-Fraumeni
syndrome (LFS, OMIM 151623), an autosomal dominant highly
penetrant cancer predisposition syndrome characterized by a
variety of early onset tumors [1,2,3]. LFS is associated with an
increase in overall cancer incidence in affected individuals and an
early age of cancer onset [4]. Many patients are affected in early
childhood, most often by sarcomas, brain and adrenocortical
tumors [5]. However, there are many families with a hereditary
predisposition to cancer suggestive of LFS who do not meet the
classical clinical diagnostic criteria and yet still carry TP53
mutations; less rigorous criteria were therefore developed [6,7,8].
Different mutant p53 proteins may have diverse functional and
biological effects, which could partially explain the heterogeneity
reported between Li-Fraumeni families [9]. Tumor spectrum,
severity and phenotype can be associated with other germline
genetic factors [10,11] and/or increase in DNA copy number
variation [12,13].
While 70% of the patients diagnosed with classical LFS have
mutations in TP53 [3], less than 20% of cases classified using less
stringent criteria carry mutation in the gene. This raises the
possibility of other causative germline gene mutations for LFS, or
of patients with mosaicism for germline mutations, undetectable
using current methods for TP53 screening. Identification of TP53
mutation has important clinical implications for early detection
and treatment of associated neoplasms through clinical surveil-
lance [14].
Improved sequencing technologies offer unprecedented oppor-
tunities for investigating the role of rare genetic variation in
common disease. The current study provides new insights into the
role of mosaic genetic variants in cancer, and the use of sequencing
technologies for their identification. We describe a child presenting
with metastatic neuroblastoma and two soft tissue tumors within
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the first 2 years of life, in the absence of a family history of cancer.
Germline mutation of TP53 was undetectable by conventional
Sanger sequencing but identified by whole exome sequencing.
This mutation was screened in three tumors, which displayed high
rates of the mutated allele. Further analysis in the blood from the
child’s neonatal blood spot test (Guthrie card) showed the
mutation was present at birth with the same mosaic pattern.
Material and Methods
Patient samples
For using of parents and child samples, written informed
consent for germline genetic analysis, including whole exome
sequencing, was obtained from the parents of the index case
patient in this study using standard UK clinical National Health
Service consent procedures. Research Governance approval for
detailed genetic analysis was provided by the Great Ormond
Street Hospital Research and Development Department (approval
11MH09).
DNA and RNA extraction
DNA from frozen samples and Guthrie card was extracted with
QIAamp DNA Mini Kit (Qiagen) following the manufacturer’s
protocol. Paraffin blocks were cut as 8 mm sections on plain glass
slides. Targeted regions for sampling were marked on adjacent
hematoxylin and eosin sections by the study pathologist and
recovered by scrape macrodissection. Between 3 and 20 sections
were macrodissected depending on the tissue sample’s size. DNA
from formalin-fixed paraffin embedded sections was extracted with
QIAamp DNA FFPE Tissue Kit (Qiagen) according to the
manufacturer’s instructions. RNA from frozen tumour sample was
extracted using the RNeasy minikit (Qiagen) and cDNA synthe-
sized using the SuperScript III (Invitrogen), using standard
protocols.
Whole exome sequencing
Whole exome sequencing from genomic (native) DNA of the
child (sample PD9058b) and his parents was performed by BGI,
Shenzhen, China, on an Illumina HiSeq DNA Analyzer using
Agilent SureSelect Human All Exon 50 Mb for target enrichment.
Forty to fifty percent of the target region had a minimum coverage
of 30X. Sequencing reads were aligned to the human genome
(NCBI build 37) using the BWA algorithm on default settings.
Reads which were unmapped, PCR-derived duplicates or reads
outside the targeted region of the genome were excluded from the
analysis.
Variant calling
The CaVEMan (cancer variants through expectation maximi-
zation) algorithm was used to call single nucleotide substitutions
[15]. To call insertions and deletions, we used split-read mapping
implemented as a modification of the Pindel algorithm [15].
Mutations were annotated to Ensembl version 58. Post-processing
filters were applied to the output to improve specificity. Variants of
the final data set were inspected manually to identify potentially
genuine variants. A single candidate variant was identified, which
was validated as described below.
Validation by targeted resequencing
Two independent samples of genomic (native) DNA derived
from peripheral blood of the child (PD9058b3, PD9058b4) as well
as parental DNA were enriched for TP53 through a custom-made
bait set (Agilent) and sequenced on an Illumina MiSeq Personal
Sequencer.
Sanger sequencing and Deep PCR amplicon sequencing
Primers flanking TP53 exon 7, where the mutation is located,
were retrieved from the IARC TP53 database. PCR reactions
were performed using the Platinum Taq DNA Polymerase PCR
kit (Life Technologies). Amplicons were sequenced using the
BigDye terminator cycle sequencing kit and an ABI 3130
automated sequencer (Applied Biosystems). Sequencing traces
were analyzed with GeneScreen (http://dna.leeds.ac.uk/
genescreen/) followed by visual inspection, with reference to the
human genome reference sequence, build hg19/GRCh37 (http://
genome.ucsc.edu). PCR-amplification and Sanger sequencing of
the cDNA were carried out with primers in flanking exons 6 and 8.
All primers were tagged for library construction (sequences
available on request).
Indexed libraries of the PCR products were prepared using the
Illumina Nextera XT library preparation kit and protocol, and
were sequenced with the Illumina MiSeq system, generating
26150-bp reads. Only sequences that passed quality control
coverage metrics were used, generating median coverage greater
than 200,000 for DNA samples and 100 for the cDNA sample
across TP53 exon 7 (average median coverage 113,222x). The
ultra-deep sequence data were aligned to the reference genome
and variants called using the standard MiSeq Reporter pipeline.
Variant quality and sequence read counts were then assessed using
the Integrative Genomics Viewer (IGV) version 2.3 [16].
Immunohistochemistry
One tumor-rich section per case was selected for immunohis-
tochemical analysis of TP53. 4 mm sections of FFPE tissue were
stained with mouse anti-human monoclonal antibody (clone DO-7
from Leica, cat# PA0057) using the Leica BOND-MAX
automated system. Antigen retrieval was performed using the
BOND-MAX heat induced epitope retrieval 2 program for 20
minutes. Staining was evaluated by the pathologist.
Results
Clinical presentation with multiple tumours
The patient, a thriving male infant, presented at the age of 9
months with a lump in his left groin, which was excised and
diagnosed as a benign myofibroblastic proliferation. He had no
relevant past medical history, and there was no family history
indicative of an underlying cancer predisposition syndrome. Two
months later he re-presented with a lump in the ipsilateral pelvic/
inguinal region. The histological appearance this time was of
sarcoma NOS, with tumor close to the resection margins but no
evidence of metastatic disease on staging investigations. He
received adjuvant chemotherapy (Vincristine and Dactinomycin)
for 5 months. End of treatment imaging revealed a mass adjacent
to the right kidney, a biopsy of which showed neuroblastoma with
MYCN amplification (hundreds of copies ofMYCN probe in double
minute pattern). A staging MIBG scan identified widespread
metastatic disease. Treatment for high risk neuroblastoma was
therefore commenced with first and second line induction
chemotherapy. He then developed an orbital swelling caused by
an underlying mass, which was shown to be a neuroblastoma on
biopsy. MYCN amplification this time, however, was seen in
homogeneously staining regions rather than in the double minute
pattern, which raised the possibility of metachronous neuroblas-
toma, rather than metastatic progression. The child failed to
respond to further treatment, and died at age 26 months.
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Evaluation of germline and tumour TP53 mutation status
As part of a screen for known cancer predisposition syndromes,
DNA isolated from both the child’s and his parents’ blood was
sequenced by capillary electrophoresis in a clinical diagnostic
laboratory to detect mutations in known cancer associated genes,
including TP53, ALK and SDH. No mutations were found by
conventional analysis of sequencing data in the child or his
parents. Whole exome sequencing of the child’s and his parent’s
DNA samples was performed to screen more widely for
pathogenic germline mutations. Sequence analysis revealed a
c.743 G.A, p.Arg248Gln (CCDS11118.1) variant in TP53, a
pathogenic TP53 mutation known to cause Li Fraumeni
syndrome. The mutation was absent from the parents’ DNA.
Interestingly, the variant was present in only approximately 20%
of sequencing reads, suggesting that the patient was mosaic for
TP53 (Figure 1A). To validate the variant, DNA samples from
three separate blood samples of the child were re-sequenced by
conventional capillary sequencing in the diagnostic laboratory and
the data this time manually inspected. A low level variance of the
variant base was seen in all three samples. These levels, if detected,
would not normally be reported as significant (Figure 1B).
Deep sequencing of the coding sequence of TP53 was
performed in two DNA samples of the child’s blood as well as
each of the parents’ blood DNA, using custom-made bait capture
for enrichment of target regions, which confirmed the presence of
the variant as mosaic in the child (variant allele fraction 3.3% and
12.5%), and its absence from parental DNA (Figure 1A).
Ultra deep sequencing for the target region by PCR was next
performed on DNA derived from blood of the patient’s newborn
blood spot (Guthrie) Card, from the two frozen neuroblastoma
tumor samples, from the formalin-fixed paraffin embedded
sarcoma NOS sample, and from one matched cDNA sample
from the sarcoma. Analysis of the Guthrie card showed that
around 14% of the blood cells had the mutant allele at the time the
child was born. In the tumor cases the results showed homozy-
gosity (range 86 to 97%) for the variant, consistent with genomic
loss of the wild type allele as a tumour promoting event in
common between the different cancers (Figure 1B). Immunohis-
tochemistry of p53 disclosed strong nuclear staining in all tumors,
typical of TP53 mutations that interfere with p53 protein function
(Figure 1C,D).
Discussion
We present the case of a young boy with severe Li Fraumeni
syndrome who has a de novo constitutional TP53 variant that is
mosaic and affects at least two germ layers. Co-occurrence of a
normal cell line and a cell line carrying the mutation constitute a
mosaicism, which can be associated only with post-zygotic de novo
mutations [17]. To our knowledge, we have demonstrated the
earliest documented occurrence of a cancer initiating TP53 point
mutation in human embryogenesis. Furthermore, our report
illustrates the utility of, and necessity for, taking next generation
sequencing (NGS) technologies into clinical practice.
Studies of human in vitro fertilized embryos show that mosaicism
is common from development to adulthood [18]. The use of more
sensitive methods is increasing detection of genome variation in
both disease and in healthy individuals, as demonstrated by copy
number alterations, genomic rearrangements single nucleotide
variation, repeat expansions and microsatellite instabilities
[18,19,20,21].
Of biological interest is that the variant drives the formation of
cancers derived from two different germ layers. Therefore, a
developmental stage during which the variant arose can be
defined. Neuroblastoma arises from the neural crest, which is
derived from ectoderm. Sarcomas and blood cells are of
mesodermal origin. The TP53 variant therefore must have arisen
in an embryonic cell that contributed to both the mesodermal and
the ectodermal lineages, which segregate during gastrulation. This
implies that the mutation arose prior to formation of the three
germ layers.
A reappraisal of the incidence of mosaicism has been made
possible by new sequencing technologies [18]. It is interesting
in this context that human embryos analyzed by single cell
genomic analysis have recently been shown to have a high
incidence of abnormal chromosome complements [22]. Previ-
ously, a case of constitutional TP53 mosaicism also with a
severe phenotype was observed in a girl who developed two
malignancies of mesodermal origin, between the ages of one
and five years [17]. This patient’s variant (R282W) was
detectable by capillary sequencing and shown to be absent
from ectodermal tissue. Other cancer-predisposing monoge-
netic diseases in which pathogenic mosacisim has been
documented include neurofibromatosis and familial adenoma-
tous polyposis [23,24,25,26] though mosacisim was associated
with less severe phenotypes in these diseases. RB1 mosaicism,
on the other hand, has also been reported to cause a high
expressivity phenotype [27].
The practical aspect this report highlights is the limitation of the
use of Sanger sequencing in clinical practice to detect pathogenic
germline variants. Furthermore, using NGS techniques, quality
control frequency filters tuned to detect heterozygous variants may
be too stringent to identify mosaic variants. Indeed standard
processing filters of two independent variant calling algorithms
excluded the TP53 mutation on initial analysis.
Of note, by sequencing four different DNA samples of the
child, we were able to demonstrate variation of the variant allele
fraction, ranging from 3.3 to 20%, with significant differences
observed between two samples. This indicates that the relative
number of circulating blood cell clone may be changeable, thus
presenting further challenges for routine detection. However,
reliable identification of germline TP53 mutation even at a low
mosaic level is very important because it affects clinical cancer
management, with many clinicians opting to avoid radiotherapy
or DNA damaging agents if possible. We speculate that as deep
sequencing replaces Sanger sequencing in clinical genetics
laboratories more cases of genetic diseases driven by mosaic
mutations will surface.
Figure 1. A. Mutant read frequency in different samples. The patient’s blood samples were all taken around the time of neuroblastoma diagnosis.
Numbers of sequencing reads per sample are displayed in the top level. * p = 0.01, comparing mutant read count frequencies between samples
PD9058b3 and PD9058b with Fisher’s exact test. Differences between PD9058b2 and sample b/b3 are not significant (p.0.05). B. Capillary
sequencing of control germline DNA (Reference sequence) and patient’s blood samples extracted at three time points, showing very low level of
adenine (black arrow). The guanine (black peak) dropped approximately between 8–17% relative to control, as given by the software, which would
not usually be classed as significant when looking for heterozygous germline mutations. C and D. Immunohistochemistry to show strong nuclear
staining p53 in neuroblastoma (C) and sarcoma NOS (D).
doi:10.1371/journal.pone.0096531.g001
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